Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5605 Target Snapshot

TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 · SINGLE PROTEIN · Homo sapiens

47Compounds
13Assays
0Approved Drugs
38.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q15750. Use UniProt Q15750 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q15750 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 as ChEMBL target CHEMBL5605, mapped to UniProt Q15750. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
TGF-beta-activated kinase 1 and MAP3K7-binding protein 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5605
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q15750
TGF-beta-activated kinase 1 and MAP3K7-binding protein 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 is the right protein anchor across sources, using UniProt Q15750 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTGF-beta-activated kinase 1 and MAP3K7-binding protein 1
UniProt AccessionQ15750
Component TypeProtein
Sequence Length504 aa

TGF-beta-activated kinase 1 and MAP3K7-binding protein 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as TGF-beta-activated kinase 1 and MAP3K7-binding protein 1, mapped to UniProt Q15750. Sequence length is 504 aa.

Mapped IDQ15750
Review nameTGF-beta-activated kinase 1 and MAP3K7-binding protein 1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

1
Phase II
Assay Mix

Activity Type Distribution

IC5038.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3953067 8.51 IC50 3.1 Preclinical
CHEMBL3916326 8.37 IC50 4.3 Preclinical
CHEMBL3924740 8.36 IC50 4.4 Preclinical
CHEMBL3919781 8.28 IC50 5.2 Preclinical
CHEMBL3917140 8.15 IC50 7.0 Preclinical
CHEMBL3898170 7.89 IC50 13.0 Preclinical
CHEMBL3912681 7.8 IC50 16.0 Preclinical
CHEMBL3905384 7.72 IC50 19.0 Preclinical
CHEMBL3901893 7.48 IC50 33.0 Preclinical
CHEMBL388978 7.46 IC50 35.0 Preclinical
Distribution

pChEMBL Value Distribution

1
5.0
3
5.5
12
6.0
7
6.5
7
7.0
3
7.5
4
8.0
1
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

13
Total Assays
38
Tested Compounds
1
Assay Types
Binding — 13 assays, 38 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 11 38 6.9
cell-based format 2 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine